AU2006278406B2 - A novel peptide involved in energy homeostasis - Google Patents

A novel peptide involved in energy homeostasis Download PDF

Info

Publication number
AU2006278406B2
AU2006278406B2 AU2006278406A AU2006278406A AU2006278406B2 AU 2006278406 B2 AU2006278406 B2 AU 2006278406B2 AU 2006278406 A AU2006278406 A AU 2006278406A AU 2006278406 A AU2006278406 A AU 2006278406A AU 2006278406 B2 AU2006278406 B2 AU 2006278406B2
Authority
AU
Australia
Prior art keywords
enhol
mice
subject
seq
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006278406A
Other languages
English (en)
Other versions
AU2006278406A1 (en
Inventor
Andrew A. Butler
James L. Trevaskis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2006278406A1 publication Critical patent/AU2006278406A1/en
Application granted granted Critical
Publication of AU2006278406B2 publication Critical patent/AU2006278406B2/en
Priority to AU2010202600A priority Critical patent/AU2010202600B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2006278406A 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis Ceased AU2006278406B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202600A AU2010202600B2 (en) 2005-08-05 2010-06-22 A novel peptide involved in energy homeostasis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70594005P 2005-08-05 2005-08-05
US60/705,940 2005-08-05
PCT/US2006/030686 WO2007019426A2 (en) 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202600A Division AU2010202600B2 (en) 2005-08-05 2010-06-22 A novel peptide involved in energy homeostasis

Publications (2)

Publication Number Publication Date
AU2006278406A1 AU2006278406A1 (en) 2007-02-15
AU2006278406B2 true AU2006278406B2 (en) 2010-03-25

Family

ID=37727967

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006278406A Ceased AU2006278406B2 (en) 2005-08-05 2006-08-07 A novel peptide involved in energy homeostasis
AU2010202600A Ceased AU2010202600B2 (en) 2005-08-05 2010-06-22 A novel peptide involved in energy homeostasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202600A Ceased AU2010202600B2 (en) 2005-08-05 2010-06-22 A novel peptide involved in energy homeostasis

Country Status (10)

Country Link
US (4) US20090253619A1 (enExample)
EP (1) EP1928487A4 (enExample)
JP (1) JP2009502208A (enExample)
KR (1) KR101004662B1 (enExample)
CN (1) CN101505786A (enExample)
AU (2) AU2006278406B2 (enExample)
CA (1) CA2618047C (enExample)
IL (2) IL189065A (enExample)
RU (2) RU2409590C2 (enExample)
WO (1) WO2007019426A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
EP3159331A1 (en) 2010-05-05 2017-04-26 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US11246912B2 (en) * 2017-08-30 2022-02-15 Hadasit Medical Research Services & Development Ltd. Methods for treating and diagnosing metastatic liver cancer
US11969460B2 (en) * 2018-06-08 2024-04-30 Saint Louis University Methods and compositions for treating decreased cognitive ability
CN110028570A (zh) * 2018-10-31 2019-07-19 华中科技大学 一种肌肉素的表达方法及其在代谢疾病中的应用
WO2024263938A2 (en) * 2023-06-23 2024-12-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Using enho gene therapy to treat cardiometabolic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078345C1 (ru) * 1992-04-03 1997-04-27 Аникеева Светлана Петровна Способ получения сывороточного белкового препарата, влияющего на активность окислительно-энергетического обмена
US20030096951A1 (en) * 1998-08-14 2003-05-22 Kenneth Jacobs Secreted proteins and polynucleotides encoding them

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009552A1 (en) * 1998-08-14 2000-02-24 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO2002070539A2 (en) * 2001-03-05 2002-09-12 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
AU2006278406A1 (en) 2007-02-15
CA2618047C (en) 2015-04-14
US20160102126A1 (en) 2016-04-14
IL189065A (en) 2012-10-31
WO2007019426A2 (en) 2007-02-15
RU2010119559A (ru) 2011-11-20
AU2010202600A1 (en) 2010-07-15
US20130231280A1 (en) 2013-09-05
EP1928487A4 (en) 2009-11-04
US8518892B2 (en) 2013-08-27
CA2618047A1 (en) 2007-02-15
WO2007019426A3 (en) 2009-04-23
CN101505786A (zh) 2009-08-12
IL189065A0 (en) 2008-08-07
IL207764A0 (en) 2010-12-30
KR20080042866A (ko) 2008-05-15
RU2008108509A (ru) 2009-09-10
AU2010202600B2 (en) 2012-07-19
US20090253619A1 (en) 2009-10-08
KR101004662B1 (ko) 2011-01-03
JP2009502208A (ja) 2009-01-29
US20100299769A1 (en) 2010-11-25
RU2409590C2 (ru) 2011-01-20
EP1928487A2 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
Lockhart et al. GDF15: a hormone conveying somatic distress to the brain
Münzberg et al. Leptin receptor action and mechanisms of leptin resistance
US20160102126A1 (en) Novel Peptides Involved in Energy Homeostasis
FR2767135A1 (fr) Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
EP1180114B1 (en) Use of resisitin specific antibodies in the treatment of diabetes
Wang et al. Low-density lipoprotein receptor-related protein 6 regulates cardiomyocyte-derived paracrine signaling to ameliorate cardiac fibrosis
AU2010257887B2 (en) SorCS1-like agent for use in the treatment of insulin resistance and diseases related thereto
US20090104203A1 (en) Compositions and Methods for Regulating Osteoclast Differentiation, Activation and Bone Resorption
CN102816205B (zh) β抑制蛋白1、其片段及其应用
CN103140234B (zh) 用于治疗肾病综合征和有关病症的方法
CA3207108A1 (en) Methods for treatment of nephrotic syndrome and related conditions
US20240342244A1 (en) Isthmin Protein Therapeutics for the Treatment of Non-Alcoholic Fatty Liver Disease
PT1701978E (pt) Utilização de caderina-t solúvel no tratamento de distúrbios metabólicos
HK1135608A (en) A novel peptide involved in energy homeostasis
US20040076965A1 (en) MIA-2 protein
EP1824518A2 (en) Diagnosis of hyperinsulinemia and type ii diabetes and protection against same based on proteins differentially expressed in serum
Rajala Functional characterization of resistin, a novel adipokine
WO2007002830A2 (en) Diagnosis of and protection from hyperinsulinemia and type ii diabetes
Pajvani Functional consequences of adiponectin oligomerization state: The role of adiponectin in maintaining systemic insulin sensitivity
MELANOCORTIN Karima Begriche, Peter R. Levasseur 2, Jingying Zhang4, Jari Rossi1, Danielle Skorupa1, Laura A. Solt3, Brandon Young1, Thomas P. Burris3, Daniel L. Marks2, Randall L. Mynatt4 and Andrew A. Butler.
Patel A role for CEACAM2 in insulin homeostasis and action
EP2010564A2 (en) The homeobox transcription factor bsx and uses thereof for treating diseases, in particular obesity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired